
    
      Study JGCB will consist of the following parts:

      Part 1 - Dose Escalation to maximum tolerated dose in each arm.

      Arm A - LY2584702 + Erlotinib in participants with advanced or metastatic cancer.

      Arm B - LY2584702 + Everolimus in participants with advanced or metastatic cancer.

      Part 2 - Dose Confirmation of maximum tolerated dose from each arm in Part 1.

      Arm A - LY2584702 + Erlotinib in participants with advanced or metastatic non-small cell lung
      cancer.

      Arm B - LY2584702 + Everolimus in participants with advanced renal cell carcinoma after
      treatment failure with sunitinib or sorafenib, or advanced neuroendocrine tumors.
    
  